## Tobias Sjöblom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/798471/publications.pdf

Version: 2024-02-01

82 papers 14,261 citations

147801 31 h-index 81 g-index

86 all docs

86 docs citations

86 times ranked 22743 citing authors

#	Article	IF	CITATIONS
1	Profiling chromatin accessibility in formalin-fixed paraffin-embedded samples. Genome Research, 2022, 32, 150-161.	5.5	16
2	KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer. Frontiers in Oncology, 2022, 12, 826073.	2.8	15
3	Next Generation Plasma Proteomics Identifies High-Precision Biomarker Candidates for Ovarian Cancers, 2022, 14, 1757.	3.7	12
4	Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions. Cancers, 2022, 14, 3225.	3.7	2
5	Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. Acta Oncológica, 2021, 60, 842-849.	1.8	16
6	Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. Radiotherapy and Oncology, 2021, 157, 70-77.	0.6	10
7	Accurate population-based model for individual prediction of colon cancer recurrence. Acta Oncol $ ilde{A}^3$ gica, 2021, 60, 1241-1249.	1.8	6
8	Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 225.	8.6	13
9	FACT-seq: profiling histone modifications in formalin-fixed paraffin-embedded samples with low cell numbers. Nucleic Acids Research, 2021, 49, e125-e125.	14.5	10
10	Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. Pharmaceuticals, 2021, 14, 57.	3.8	27
11	A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer. Cancers, 2021, 13, 16.	3.7	21
12	The Immune Landscape of Colorectal Cancer. Cancers, 2021, 13, 5545.	3.7	14
13	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. Acta Oncológica, 2020, 59, 417-426.	1.8	22
14	Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. Annals of Surgical Oncology, 2020, 27, 1036-1045.	1.5	18
15	Targeting tumor vulnerabilities associated with loss of heterozygosity. Molecular and Cellular Oncology, 2020, 7, 1759390.	0.7	0
16	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N â€Acetyltransferase NAT2. Angewandte Chemie, 2020, 132, 14448-14452.	2.0	2
17	Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?. Cancers, 2020, 12, 3308.	3.7	25
18	Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort. Scientific Reports, 2020, 10, 19304.	3.3	10

#	Article	IF	CITATIONS
19	88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer. Annals of Oncology, 2020, 31, S276.	1.2	13
20	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	3.7	13
21	Restoration of KMT2C/MLL3 in human colorectal cancer cells reinforces genome-wide H3K4me1 profiles and influences cell growth and gene expression. Clinical Epigenetics, 2020, 12, 74.	4.1	22
22	Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine <i>N</i> â€Acetyltransferase NAT2. Angewandte Chemie - International Edition, 2020, 59, 14342-14346.	13.8	18
23	Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy. Nature Communications, 2020, 11, 1308.	12.8	18
24	Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer. Scientific Reports, 2020, 10, 22436.	3.3	5
25	Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. British Journal of Cancer, 2019, 121, 303-311.	6.4	5
26	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	3.3	39
27	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	2.5	23
28	Determining the use of preoperative (chemo) radiotherapy in primary rectal cancer according to national and international guidelines. Radiotherapy and Oncology, 2019, 136, 106-112.	0.6	10
29	Multispectral imaging for quantitative and compartmentâ€specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. Journal of Pathology, 2018, 244, 421-431.	4.5	159
30	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol $\tilde{A}^3$ gica, 2018, 57, 187-194.	1.8	52
31	VEGF receptorâ€2/neuropilin 1 <i>trans</i> à€complex formation between endothelial and tumor cells is an independent predictor of pancreatic cancer survival. Journal of Pathology, 2018, 246, 311-322.	4.5	28
32	Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells. Genome Medicine, 2018, 10, 2.	8.2	6
33	Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. European Journal of Surgical Oncology, 2018, 44, 1858-1864.	1.0	5
34	Targeted DNA sequencing and in situ mutation analysis using mobile phone microscopy. Nature Communications, 2017, 8, 13913.	12.8	118
35	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. Cancer Research, 2017, 77, 1730-1740.	0.9	29
36	A pathology atlas of the human cancer transcriptome. Science, 2017, 357, .	12.6	2,570

#	Article	IF	CITATIONS
37	A new distance measure for non-identical data with application to image classification. Pattern Recognition, 2017, 63, 384-396.	8.1	10
38	Loss of DIP2C in RKO cells stimulates changes in DNA methylation and epithelial-mesenchymal transition. BMC Cancer, 2017, 17, 487.	2.6	29
39	Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity. Oncotarget, 2017, 8, 30217-30234.	1.8	12
40	Somatic <i>PRDM2</i> c.4467delA mutations in colorectal cancers control histone methylation and tumor growth. Oncotarget, 2017, 8, 98646-98659.	1.8	13
41	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood, 2016, 127, 1007-1016.	1.4	130
42	Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6217-6227.	7.0	26
43	Computational and molecular tools for scalable rAAV-mediated genome editing. Nucleic Acids Research, 2015, 43, e30-e30.	14.5	5
44	Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7743-7748.	7.1	26
45	Tumor Vessel Up-Regulation of INSR Revealed by Single-Cell Expression Analysis of the Tyrosine Kinome and Phosphatome in Human Cancers. American Journal of Pathology, 2015, 185, 1600-1609.	3.8	24
46	<i>In situ</i> sequencing identifies <i><scp>TMPRSS2–ERG</scp></i> fusion transcripts, somatic point mutations and gene expression levels in prostate cancers. Journal of Pathology, 2014, 234, 253-261.	4.5	12
47	A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant <i>In Vitro</i> Multicompound Analyses. Molecular Cancer Therapeutics, 2014, 13, 1964-1976.	4.1	16
48	Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15. Cancer Research, 2014, 74, 3408-3417.	0.9	101
49	Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. BMC Genomics, 2013, 14, 165.	2.8	33
50	Automated serial extraction of DNA and RNA from biobanked tissue specimens. BMC Biotechnology, 2013, 13, 66.	3.3	18
51	STC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer. Cancer Research, 2013, 73, 1287-1297.	0.9	144
52	Identification of driver genes in microsatellite-unstable colorectal cancers. Colorectal Cancer, 2013, 2, 515-523.	0.8	0
53	In situ mutation detection and visualization of intratumor heterogeneity for cancer research and diagnostics. Oncotarget, 2013, 4, 2407-2418.	1.8	42
54	Somatic Mutations in CCK2R Alter Receptor Activity that Promote Oncogenic Phenotypes. Molecular Cancer Research, 2012, 10, 739-749.	3.4	16

#	Article	lF	Citations
55	Scalable In Situ Hybridization on Tissue Arrays for Validation of Novel Cancer and Tissue-Specific Biomarkers. PLoS ONE, 2012, 7, e32927.	2.5	11
56	Somatic mutations in the notch, NFâ∈KB, PIK3CA, and hedgehog pathways in human breast cancers. Genes Chromosomes and Cancer, 2012, 51, 480-489.	2.8	58
57	Automated Genotyping of Biobank Samples by Multiplex Amplification of Insertion/Deletion Polymorphisms. PLoS ONE, 2012, 7, e52750.	2.5	9
58	Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes and Cancer, 2011, 50, 82-94.	2.8	79
59	Targeted resequencing of candidate genes using selector probes. Nucleic Acids Research, 2011, 39, e8-e8.	14.5	66
60	Structural Alterations from Multiple Displacement Amplification of a Human Genome Revealed by Mate-Pair Sequencing. PLoS ONE, 2011, 6, e22250.	2.5	11
61	Prognostic Significance of Stromal Platelet-Derived Growth Factor $\hat{l}^2$ -Receptor Expression in Human Breast Cancer. American Journal of Pathology, 2009, 175, 334-341.	3.8	215
62	Molecular pathways in tumor progression: from discovery to functional understanding. Molecular BioSystems, 2009, 5, 902.	2.9	30
63	Sustained TGFÎ <sup>2</sup> exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene, 2008, 27, 1218-1230.	5.9	193
64	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16224-16229.	7.1	285
65	Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Current Opinion in Oncology, 2008, 20, 66-71.	2.4	21
66	Large-scale identification of novel transcripts in the human genome. Genome Research, 2007, 17, 287-292.	5.5	15
67	In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor $\hat{l}^2$ Using a Generalized Proximity Ligation Method. Molecular and Cellular Proteomics, 2007, 6, 1500-1509.	3.8	197
68	A multidimensional analysis of genes mutated in breast and colorectal cancers. Genome Research, 2007, 17, 1304-1318.	5.5	121
69	The Genomic Landscapes of Human Breast and Colorectal Cancers. Science, 2007, 318, 1108-1113.	12.6	3,049
70	The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science, 2006, 314, 268-274.	12.6	3,130
71	The colorectal microRNAome. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3687-3692.	7.1	890
72	Oral Imatinib Mesylate (STI571/Gleevec) Improves the Efficacy of Local Intravascular Vascular Endothelial Growth Factor-C Gene Transfer in Reducing Neointimal Growth in Hypercholesterolemic Rabbits. Circulation, 2004, 109, 1140-1146.	1.6	47

#	Article	IF	CITATIONS
73	Preferential oxidation of the second phosphatase domain of receptor-like PTP- $\hat{l}\pm$ revealed by an antibody against oxidized protein tyrosine phosphatases. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1886-1891.	7.1	121
74	Platelet-Derived Growth Factor Production by B16 Melanoma Cells Leads to Increased Pericyte Abundance in Tumors and an Associated Increase in Tumor Growth Rate. Cancer Research, 2004, 64, 2725-2733.	0.9	174
75	PDGF receptors as cancer drug targets. Cancer Cell, 2003, 3, 439-443.	16.8	449
76	Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic and Medicinal Chemistry, 2003, 11, 2007-2018.	3.0	62
77	Transgenic Overexpression of Platelet-Derived Growth Factor-C in the Mouse Heart Induces Cardiac Fibrosis, Hypertrophy, and Dilated Cardiomyopathy. American Journal of Pathology, 2003, 163, 673-682.	3.8	137
78	Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Research, 2002, 62, 5476-84.	0.9	356
79	Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Research, 2001, 61, 5778-83.	0.9	206
80	Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Research, 2000, 60, 6723-9.	0.9	47
81	Characterization of the chronic myelomonocytic leukemia associated TEL-PDGFÎ <sup>2</sup> R fusion protein. Oncogene, 1999, 18, 7055-7062.	5.9	36
82	The dermatofibrosarcoma protuberans-associated collagen type lalpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Research, 1999, 59, 3719-23.	0.9	216